Company Overview
Snapshot
Founded in January 2017 by Bentzi Gruber, Guy Zur, Gerry Waintraub, and Taire Rubin, GWave operates with 1–10 employees. The company has raised $21.1M across 3 funding rounds from 2 investors. In August 2023, GWave closed its Series C funding round, coinciding with the unveiling of new clinical data for its GWave technology.
Business overview
GWave, developed by Hagar Technology, specializes in noninvasive glucose monitoring within the Health Tech & Life Sciences sector. The company's core product is a glucometer that uses radio frequency waves and proprietary AI algorithms to continuously measure blood glucose levels in real time. This technology aims to provide cost-efficient, compact, and accurate measurements, serving markets focused on diabetes management and digital therapeutics. GWave's system connects seamlessly to Bluetooth and smartphones, offering a user-friendly experience with automated alarms and cloud-based data storage for users, caretakers, and medical professionals.
Strategic signal
In November 2021, GWave's HAGAR GWave technology was awarded FDA Breakthrough Device Designation. This designation signals significant regulatory validation for the company's non-invasive glucose monitoring solution, indicating its potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. For investors, this highlights a critical de-risking milestone and potential for accelerated market entry, positioning GWave as a frontrunner in the medical device and digital therapeutics space.
Log in to access full profile ›Company Intelligence Q&A
- What is GWave's primary technology?
- GWave utilizes radio frequency waves combined with proprietary AI algorithms to provide continuous, noninvasive blood glucose monitoring in real time.
- When was GWave awarded FDA Breakthrough Device Designation?
- In November 2021, GWave was awarded FDA Breakthrough Device Designation for its noninvasive glucose monitoring technology, recognizing its potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
- When did GWave close its Series C funding round?
- GWave closed its Series C funding round in August 2023, securing $5 million to advance its non-invasive glucose monitoring technology.
- What was the total funding raised by GWave?
- GWave has raised a total of $21.1 million across three funding rounds. The company secured $5 million in its Series C round in August 2023, and $11.7 million in its Series B round in August 2021, with Columbia Pacific Capital Partners as a lead investor.
- When did GWave raise its Series B funding?
- In August 2021, GWave raised its Series B funding round, with Columbia Pacific Capital Partners as a lead investor.